PREDICTIVE DIAGNOSTICS FOR CANCER IMMUNOTHERAPY
Cancer immunotherapy harness the immune system to eliminate cancer. Immune checkpoint blockade and chimeric antigen receptor T cell therapies have achieved remarkable success in some advanced cancer patients, however there is still a significant proportion of patients that don’t respond to treatments. Biomarkers that can be used to screen for the benefit-seeking population, and guide the development of new combination therapies are essential.
Pyxis Diagnostics develops a unique platform to enable the identification of predictive biomarkers in the field of immuno-oncology by computational modeling the immune suppressive networks in tumor microenvironment.
CTO – Dr. Reut Yosef